Castle Biosciences Holds Annual Stockholders Meeting

Castle Biosciences ( (CSTL) ) just unveiled an announcement.

On May 22, 2025, Castle Biosciences held its annual meeting of stockholders, where key decisions were made. Stockholders elected three Class III Directors to serve until 2028, ratified KPMG LLP as the independent accounting firm for 2025, approved executive compensation, and amended the company’s certificate of incorporation to limit officer liability. These decisions reflect the company’s ongoing efforts to strengthen governance and operational frameworks.

The most recent analyst rating on (CSTL) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.

Spark’s Take on CSTL Stock

According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.

Castle Biosciences shows strong financial performance with substantial revenue growth, improved profitability, and positive cash flow metrics. However, technical analysis indicators reflect a bearish trend, and the valuation suggests potential overvaluation due to the negative P/E ratio. The recent earnings call provided mixed insights, with notable growth but also operational challenges. Overall, these factors result in a moderate stock score, highlighting strengths in financial health but caution in technical and valuation aspects.

To see Spark’s full report on CSTL stock, click here.

More about Castle Biosciences

Castle Biosciences, Inc. operates in the biotechnology industry, focusing on developing and commercializing diagnostic and prognostic tests for dermatologic cancers and other diseases. The company aims to provide personalized medicine solutions to improve patient outcomes.

Average Trading Volume: 462,998

Technical Sentiment Signal: Sell

Current Market Cap: $458.8M

See more data about CSTL stock on TipRanks’ Stock Analysis page.